Baxter's Norepinephrine Wins FDA Nod For Low Blood Pressure - Baxter Intl (NYSE:BAX)

The FDA has approved Baxter International Inc's BAX premix norepinephrine bitartrate in 5% dextrose injection.
Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).
According to a news release, the company's formulation of norepinephrine is the first and only manufacturer-prepared, ready-to-use formulation.
The Company offers the formulation in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths.
Baxter's formulation has a shelf life of up to 21 months in a refrigerator or up to 90 days at room temperature in overwrap. It can be stored in automated dispensing cabinets at the point of care.
Related content: Benzinga's Full FDA Calendar.
Price Action: BAX stock is up 0.12% at $81.15 during the market session on the last check Thursday.